Physician profile
Andrew Page
NPI 1164608014
$26,458.45
in general payments reported to CMS, 2019-2025
31 companies · $3,711 in 2025
The $3,711 reported for 2025 was more than what 88% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $64.45 · 2021: $9,113 · 2022: $913 · 2023: $10K · 2024: $1,973 · 2025: $3,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11K · Food and Beverage: $4,319 · Travel and Lodging: $472 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $11,250.00 |
| Food and Beverage | $4,319.42 |
| Travel and Lodging | $471.64 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,213.08 | 2020-2025 | Davinci Xi, Da Vinci Surgical System |
| Ethicon US, LLC | $1,102.89 | 2019-2025 | Echelon Circular, Stratafix, Harmonic |
| Smith+Nephew, INC. | $683.54 | 2022-2025 | Grafix, Stravix, Pico 7 |
| Abbvie INC. | $550.80 | 2021-2025 | |
| Medtronic, INC. | $347.09 | 2022-2025 | Signia, Ligasure |
| Lexington Medical, INC. | $162.88 | 2023 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Aimmune Therapeutics, INC. | $155.50 | 2024-2025 | Zenpep |
| Biocompatibles, INC. | $149.89 | 2019 | |
| Ethicon INC. | $129.12 | 2023 | N/A, Enseal, Dermabond Prineo |
| Histosonics, INC. | $127.49 | 2024 | |
| Depuy Synthes Sales INC. | $118.76 | 2023 | Matrixrib |
| Nestle Healthcare Nutrition INC. | $75.73 | 2022-2023 | |
| Novo Nordisk INC | $69.66 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.87 | 2019-2020 | |
| Baxter Healthcare | $50.84 | 2022-2024 | Floseal |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.36 | 2023-2024 | Keytruda, Dificid |
| Integra Lifesciences Corporation | $46.23 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Angiodynamics, INC. | $45.80 | 2023 | Nanoknife |
| Vivus LLC | $43.45 | 2024-2025 | Qsymia |
| Ets Wound Care LLC | $38.37 | 2025 | Mirragen Advanced Wound Matrix |
| Aroa Biosurgery Incorporated | $36.11 | 2022-2023 | |
| Davol INC. | $32.43 | 2023 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $25.34 | 2024 | Exparel |
| Kci USA, INC. | $21.03 | 2023 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
| Conmed Corporation | $20.63 | 2025 | Airseal |
| Solventum Corporation | $20.43 | 2024 | V.A.C.Ulta |
| Avanos Medical | $19.73 | 2024 | On-Q* Pump and Accessories |
| Heron Therapeutics, INC. | $18.64 | 2023 | Zynrelef |
| Boston Scientific Corporation | $17.28 | 2025 | Spyglass Discover |
| Teleflex LLC | $15.11 | 2025 | Titan Sgs Bailout Chuck |
| Civatech Oncology, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.